Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations is a phase 2, interventional study registered as NCT06229340 by N.N. Petrov National Medical Research Center of Oncology, with a registry enrolment figure of 20 participants, started 2023-10-03 and due to reach its primary completion in 2026-10-01. Interventions recorded: Leflunomide; The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab. Conditions listed: RAS Mutation; Ras (Kras or Nras) Gene Mutation; Colorectal Cancer Recurrent; Pancreas Cancer; Lung Cancer; Melanoma; Refractory Cancer. Primary outcome: Objective response rate. Sites: Russia. No results are recorded here; the registry entry is the source.